Rallybio Holdings LLC (RLYB) Noticias

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study...

Form 4 - Statement of changes in beneficial ownership of securities

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –...

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — Rallybio Corporation (Nasdaq: RLYB), a clinical-stage...

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology...

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (Nasdaq:...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

— CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 — — $75.1 Million in Cash, Cash...

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

— First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT — — Screening in the Phase 2 Clinical Trial On Track to...

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage...

Form 8-K - Current report